CJ Bioscience, Inc. (KOSDAQ:311690)
South Korea · Delayed Price · Currency is KRW 4,610.00
-190.00 (-3.96%)
At close: Jun 19, 2026
CJ Bioscience Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -23,004 | -24,005 | -32,838 | -22,913 | -34,913 | -19,272 |
Depreciation & Amortization | 3,895 | 4,013 | 4,321 | 5,146 | 3,900 | 1,562 |
Loss (Gain) From Sale of Assets | 639.62 | 638.74 | -10.89 | -8,718 | 366.99 | -10.43 |
Asset Writedown & Restructuring Costs | - | - | - | - | - | 170.67 |
Stock-Based Compensation | - | - | - | 141.5 | 543.83 | 555.76 |
Provision & Write-off of Bad Debts | - | - | - | - | - | 105.27 |
Other Operating Activities | 1,866 | 1,770 | 1,846 | 1,880 | 3,375 | 9,460 |
Change in Accounts Receivable | -104.97 | -345.91 | 88.9 | 142.18 | -70.3 | -191.24 |
Change in Inventory | -88.47 | -56.37 | 29.07 | -81.66 | 69.66 | -231.19 |
Change in Accounts Payable | 68.11 | 157.49 | 98.01 | -213.84 | 48.91 | -421.5 |
Change in Unearned Revenue | 33.64 | 35.49 | 28.67 | 119.84 | 211.49 | 53.71 |
Change in Other Net Operating Assets | -3,140 | -5,624 | -1,324 | -401.61 | 5,505 | -218.1 |
Operating Cash Flow | -19,836 | -23,416 | -27,760 | -24,899 | -20,963 | -8,437 |
Capital Expenditures | -10.66 | -10.66 | -377.59 | -4,924 | -4,145 | -952.65 |
Sale of Property, Plant & Equipment | 97.34 | 99.52 | 26.34 | 33,116 | 85.09 | 10.45 |
Cash Acquisitions | - | - | - | - | -6,239 | - |
Sale (Purchase) of Intangibles | 325.14 | 314.73 | -206.02 | -11,493 | -725.5 | -26.1 |
Investment in Securities | 19,500 | 26,500 | -67,000 | 0.21 | 18,018 | 7,158 |
Other Investing Activities | - | - | - | -0 | 171.58 | 262.42 |
Investing Cash Flow | 19,912 | 26,904 | -67,557 | 16,699 | 7,165 | 6,453 |
Short-Term Debt Issued | - | 763.73 | 1,705 | 1,305 | 2,636 | - |
Total Debt Issued | 774.99 | 763.73 | 1,705 | 1,305 | 2,636 | - |
Long-Term Debt Repaid | - | -1,843 | -1,864 | -23,077 | -1,414 | -22,768 |
Net Debt Issued (Repaid) | -1,091 | -1,079 | -159.04 | -21,772 | 1,222 | -22,768 |
Issuance of Common Stock | - | - | 39,970 | 44,977 | 50 | 73,479 |
Other Financing Activities | -365.46 | -362.62 | -311.73 | -260.87 | -280.02 | -0 |
Financing Cash Flow | -1,457 | -1,442 | 39,499 | 22,944 | 992.18 | 50,711 |
Foreign Exchange Rate Adjustments | -6.02 | -15.79 | 32.13 | 26.74 | 69.69 | 78.4 |
Miscellaneous Cash Flow Adjustments | -0 | -0 | 0 | 0 | 0 | - |
Net Cash Flow | -1,387 | 2,030 | -55,786 | 14,772 | -12,737 | 48,805 |
Free Cash Flow | -19,846 | -23,427 | -28,138 | -29,823 | -25,108 | -9,390 |
Free Cash Flow Margin | -557.05% | -634.44% | -811.70% | -534.93% | -616.19% | -215.22% |
Free Cash Flow Per Share | -1519.06 | -1793.05 | -3034.18 | -4210.07 | -4271.74 | -2208.24 |
Cash Interest Paid | 365.46 | 362.62 | 311.73 | 190.87 | 30.02 | 361.12 |
Cash Income Tax Paid | - | 38.65 | 70.74 | 1.48 | 141.56 | 5.3 |
Levered Free Cash Flow | -12,874 | -16,393 | -16,913 | -32,209 | -17,249 | -6,708 |
Unlevered Free Cash Flow | -12,521 | -16,055 | -16,546 | -31,633 | -15,522 | -3,603 |
Change in Working Capital | -3,232 | -5,833 | -1,079 | -435.09 | 5,765 | -1,008 |